Advertisement

Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies: prospective randomized clinical trial to compare ICG-99mTc-nanocolloid hybrid tracer versus 99mTc-nanocolloid

  • Ingo Stoffels
  • Julia Leyh
  • Thorsten Pöppel
  • Dirk Schadendorf
  • Joachim Klode
Original Article

Abstract

Purpose

There is some controversy about the value of sentinel lymph node excision (SLNE) in patients with head and neck malignancies. The gold standard for detection and targeted extirpation of the SLN is lymphoscintigraphy with 99mTc-nanocolloid. The purpose of this prospective randomized study was to analyse the feasibility and clinical benefit of a hybrid tracer comprising the near-infrared (NIR) fluorescent indocyanine green (ICG) and 99mTc-nanocolloid (ICG-99mTc-nanocolloid) in direct comparison with standard 99mTc-nanocolloid for guiding SLNE in patients with head and neck cutaneous malignancies.

Methods

We analysed the data from 40 clinically lymph node-negative patients with melanoma, high-risk cutaneous squamous cell carcinoma, Merkel cell carcinoma or sweat gland carcinoma who underwent SLNE with ICG-99mTc-nanocolloid (cohort A) or with the standard 99mTc-nanocolloid (cohort B).

Results

Overall SLNs were identified preoperatively in all 20 patients (100 %) in cohort A and in 18 of 20 patients (90 %) in cohort B. The SLN basin was detected preoperatively in 18 patients (90 %) in cohort A and also in 18 patients (90 %) in cohort B. SLNs were identified intraoperatively in all 20 patients (100 %) in cohort A and in 19 patients (95 %) in cohort B (p = 0.487). Metastatic SLNs were detected in 9 patients (22.5 %), 3 (15.0 %) in cohort A and 6 (30.0 %) in cohort B (p = 0.228).

Conclusion

The hybrid tracer ICG-99mTc-nanocolloid is an innovative imaging tracer, reliably and readily providing additional information for the detection and excision of SLN in the head and neck region. Therefore, SLNE with combined radioactive and NIR fluorescence guidance is an attractive option for improving the SLN detection rate in patients with cutaneous head and neck malignancies.

Keywords

Malignant melanoma Head and neck cancer Sentinel lymph node Hybrid tracer Indocyanine green 

Notes

Compliance with ethical standards

Conflicts of interest

Dr. Schadendorf reported receiving consultancy fees, having board membership, and receiving lecture fees from GlaxoSmithKline, Novartis, Amgen, Bristol-Myers Squibb, Roche, Genentech, Boehringer Ingelheim and MSD. The other authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Statement on the welfare of animals

This article does not describe any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

259_2015_3093_MOESM1_ESM.doc (30 kb)
ESM 1 (DOC 29 kb)

References

  1. 1.
    Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34.PubMedGoogle Scholar
  2. 2.
    Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17. doi: 10.1056/NEJMoa060992.CrossRefPubMedGoogle Scholar
  3. 3.
    Thomas JM. Caution with sentinel node biopsy in cutaneous melanoma. Br J Surg. 2006;93:129–30. doi: 10.1002/bjs.5255.CrossRefPubMedGoogle Scholar
  4. 4.
    Sondak VK, Zager JS, Messina JL, Thomas JM. Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol. 2007;5:483–90.PubMedGoogle Scholar
  5. 5.
    Alex JC, Krag DN, Harlow SP, Meijer S, Loggie BW, Kuhn J, et al. Localization of regional lymph nodes in melanomas of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124:135–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Wells KE, Rapaport DP, Cruse CW, Payne W, Albertini J, Berman C, et al. Sentinel lymph node biopsy in melanoma of the head and neck. Plast Reconstr Surg. 1997;100:591–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Fisher SR, O’Brien CJ. Head and neck melanomas. In: Balch CM, Houghton Jr A, Sober A, Soong SJ, editors. Cutaneous melanoma. St. Louis: Quality Medical Publishing; 2003. p. 275–96.Google Scholar
  8. 8.
    Pathak I, O’Brien CJ, Petersen-Schaeffer K, McNeil EB, McMahon J, Quinn MJ, et al. Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern? Head Neck. 2001;23:785–90. doi: 10.1002/hed.1112.CrossRefPubMedGoogle Scholar
  9. 9.
    Leiter U, Buettner PG, Bohnenberger K, Eigentler T, Meier F, Moehrle M, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol. 2010;17:129–37. doi: 10.1245/s10434-009-0780-2.CrossRefPubMedGoogle Scholar
  10. 10.
    Veenstra HJ, Wouters MW, Kroon BB, Olmos RA, Nieweg OE. Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. J Surg Oncol. 2011;104:454–7. doi: 10.1002/jso.21967.CrossRefPubMedGoogle Scholar
  11. 11.
    Stoffels I, Boy C, Poppel T, Kuhn J, Klotgen K, Dissemond J, et al. Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. JAMA. 2012;308:1007–14. doi: 10.1001/2012.jama.11030.CrossRefPubMedGoogle Scholar
  12. 12.
    Polom K, Murawa D, Rho YS, Nowaczyk P, Hunerbein M, Murawa P. Current trends and emerging future of indocyanine green usage in surgery and oncology: a literature review. Cancer. 2011;117:4812–22. doi: 10.1002/cncr.26087.CrossRefPubMedGoogle Scholar
  13. 13.
    Sugie T, Sawada T, Tagaya N, Kinoshita T, Yamagami K, Suwa H, et al. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol. 2013;20:2213–8. doi: 10.1245/s10434-013-2890-0.CrossRefPubMedGoogle Scholar
  14. 14.
    Stoffels I, Dissemond J, Pöppel T, Schadendorf D, Klode J. Intraoperative fluorescence imaging for sentinel lymph node detection: prospective clinical trial to compare the usefulness of indocyanine green vs technetium Tc 99m for identification of sentinel lymph nodes. JAMA Surg. 2015. doi: 10.1001/jamasurg.2014.3502 PubMedGoogle Scholar
  15. 15.
    Abe H, Mori T, Umeda T, Tanaka M, Kawai Y, Shimizu T, et al. Indocyanine green fluorescence imaging system for sentinel lymph node biopsies in early breast cancer patients. Surg Today. 2011;41:197–202. doi: 10.1007/s00595-009-4254-8.CrossRefPubMedGoogle Scholar
  16. 16.
    Buckle T, van Leeuwen AC, Chin PT, Janssen H, Muller SH, Jonkers J, et al. A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node. Nanotechnology. 2010;21:355101. doi: 10.1088/0957-4484/21/35/355101.CrossRefPubMedGoogle Scholar
  17. 17.
    Prieto VG, Clark SH. Processing of sentinel lymph nodes for detection of metastatic melanoma. Ann Diagn Pathol. 2002;6:257–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res. 2007;17:393–9. doi: 10.1097/CMR.0b013e3282f.CrossRefPubMedGoogle Scholar
  19. 19.
    Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist. 2002;7:271–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Klode J, Poeppel T, Boy C, Mueller S, Schadendorf D, Korber A, et al. Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies. J Eur Acad Dermatol Venereol. 2011;25:1213–21. doi: 10.1111/j.1468-3083.2010.03954.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Shumate CR, Carlson GW, Giacco GG, Guinee VF, Byers RM. The prognostic implications of location for scalp melanoma. Am J Surg. 1991;162:315–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Slingluff Jr CL, Vollmer RT, Reintgen DS, Seigler HF. Lethal “thin” malignant melanoma. Identifying patients at risk. Ann Surg. 1988;208:150–61.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Stoffels I, von der Stuck H, Boy C, Poppel T, Korber N, Weindorf M, et al. Indocyanine green fluorescence-guided sentinel lymph node biopsy in dermato-oncology. J Dtsch Dermatol Ges. 2012;10:51–7. doi: 10.1111/j.1610-0387.2011.07843.x.PubMedGoogle Scholar
  24. 24.
    Ballardini B, Santoro L, Sangalli C, Gentilini O, Renne G, Lissidini G, et al. The indocyanine green method is equivalent to the 99mTc-labeled radiotracer method for identifying the sentinel node in breast cancer: a concordance and validation study. Eur J Surg Oncol. 2013;39:1332–6. doi: 10.1016/j.ejso.2013.10.004.CrossRefPubMedGoogle Scholar
  25. 25.
    Hutteman M, Mieog JS, van der Vorst JR, Liefers GJ, Putter H, Lowik CW, et al. Randomized, double-blind comparison of indocyanine green with or without albumin premixing for near-infrared fluorescence imaging of sentinel lymph nodes in breast cancer patients. Breast Cancer Res Treat. 2011;127:163–70. doi: 10.1007/s10549-011-1419-0.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Schaafsma BE, van der Vorst JR, Gaarenstroom KN, Peters AA, Verbeek FP, de Kroon CD, et al. Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer. Gynecol Oncol. 2012;127:126–30. doi: 10.1016/j.ygyno.2012.07.002.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    van der Vorst JR, Schaafsma BE, Verbeek FP, Hutteman M, Mieog JS, Lowik CW, et al. Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. Ann Surg Oncol. 2012;19:4104–11. doi: 10.1245/s10434-012-2466-4.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Fujisawa Y, Nakamura Y, Kawachi Y, Otsuka F. Indocyanine green fluorescence-navigated sentinel node biopsy showed higher sensitivity than the radioisotope or blue dye method, which may help to reduce false-negative cases in skin cancer. J Surg Oncol. 2012;106:41–5. doi: 10.1002/jso.23045.CrossRefPubMedGoogle Scholar
  29. 29.
    Rodier JF, Velten M, Wilt M, Martel P, Ferron G, Vaini-Elies V, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol. 2007;25:3664–9. doi: 10.1200/JCO.2006.08.4228.CrossRefPubMedGoogle Scholar
  30. 30.
    Jung SY, Kim SK, Kim SW, Kwon Y, Lee ES, Kang HS, et al. Comparison of sentinel lymph node biopsy guided by the multimodal method of indocyanine green fluorescence, radioisotope, and blue dye versus the radioisotope method in breast cancer: a randomized controlled trial. Ann Surg Oncol. 2014;21:1254–9. doi: 10.1245/s10434-013-3437-0.CrossRefPubMedGoogle Scholar
  31. 31.
    Vermeeren L, van der Ploeg IM, Olmos RA, Meinhardt W, Klop WM, Kroon BB, et al. SPECT/CT for preoperative sentinel node localization. J Surg Oncol. 2010;101:184–90. doi: 10.1002/jso.21439.PubMedGoogle Scholar
  32. 32.
    Brouwer OR, Buckle T, Vermeeren L, Klop WM, Balm AJ, van der Poel HG, et al. Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med. 2012;53:1034–40. doi: 10.2967/jnumed.112.103127.CrossRefPubMedGoogle Scholar
  33. 33.
    van den Berg NS, Brouwer OR, Schaafsma BE, Matheron HM, Klop WM, Balm AJ, et al. Multimodal surgical guidance during sentinel node biopsy for melanoma: combined gamma tracing and fluorescence imaging of the sentinel node through use of the hybrid tracer indocyanine green-(99m)Tc-nanocolloid. Radiology. 2015;275:521–9. doi: 10.1148/radiol.14140322.
  34. 34.
    Van Den Berg NS, Buckle T, Kleinjan GI, Klop WM, Horenblas S, Van Der Poel HG, et al. Hybrid tracers for sentinel node biopsy. Q J Nucl Med Mol Imaging. 2014;58:193–206.Google Scholar
  35. 35.
    van der Vorst JR, Schaafsma BE, Verbeek FP, Keereweer S, Jansen JC, van der Velden LA, et al. Near-infrared fluorescence sentinel lymph node mapping of the oral cavity in head and neck cancer patients. Oral Oncol. 2013;49:15–9. doi: 10.1016/j.oraloncology.2012.07.017.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Namikawa K, Tsutsumida A, Tanaka R, Kato J, Yamazaki N. Limitation of indocyanine green fluorescence in identifying sentinel lymph node prior to skin incision in cutaneous melanoma. Int J Clin Oncol. 2014;19:198–203. doi: 10.1007/s10147-013-0524-y.CrossRefPubMedGoogle Scholar
  37. 37.
    van der Poel HG, Buckle T, Brouwer OR, Valdes Olmos RA, van Leeuwen FW. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol. 2011;60:826–33. doi: 10.1016/j.eururo.2011.03.024.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Ingo Stoffels
    • 1
    • 2
    • 3
  • Julia Leyh
    • 1
    • 2
    • 3
  • Thorsten Pöppel
    • 4
  • Dirk Schadendorf
    • 1
    • 2
    • 3
  • Joachim Klode
    • 1
    • 2
    • 3
  1. 1.Department of Dermatology, Venerology and AllergologyUniversity Hospital Essen University of Duisburg-EssenEssenGermany
  2. 2.West German Cancer CenterUniversity Duisburg-EssenEssenGermany
  3. 3.German Cancer Consortium (DKTK)EssenGermany
  4. 4.Department of Nuclear MedicineUniversity Hospital Essen University of Duisburg-EssenEssenGermany

Personalised recommendations